HealthEconomics.Com: Recent Episodes
None
In part one of a two-part series on insulin biosimilars, we’ll talk about what these new drugs could mean for the category.
Aligning evidence for regulatory requirements and global market access requirements depends on accurate forecasting which considers an ever-changing market landscape.